6059-44-5

Upstream product

• 67-56-1 methanol 
• 515-94-6 2,3-diaminopropanoic acid 
• 515-94-6 (S)-2,3-diaminopropionic acid 
• 1482-97-9 (S)-2,3-diaminopropanoic acid hydrochloride 
• 54897-59-5 2,3-diaminopropanoic acid hydrochloride 

Downstream Products

• 227098-01-3 DL-2,3-bis{[3-(3,4-dimethoxyphenyl)acryloyl]amino}propionic acid methyl ester 
• 897932-01-3 N,N-bis(3,4-dimethoxycarbonylcaffeoyl)-D,L-2,3-diaminopropionic acid methyl ester 
• 897932-28-4 DL-2,3-bis[(3,4,5-trimethoxybenzoyl)amino]propionic acid methyl ester 
• 1181818-57-4 2-phenyl-1H-imidazoline-4-carboxylic acid methyl ester 
• 77087-60-6 methyl (S)-2-amino-3-tert-butoxycarbonylaminopropanoate 
• 61040-20-8 (S)-methyl 3-amino-2-((tert-butoxycarbonyl)amino)propanoate 
• 224184-31-0 methyl DL-2,3-bis[((triphenylmethyl)thio)-acetamido]propionate 
• 1239503-28-6 methyl 2-[5-bromo-4-cyano-3-(2,4-dichlorophenyl)-2-thienyl]-4,5-dihydro-1H-imidazole-5-carboxylate 
• 2387-23-7 1,3-Dicyclohexylurea 
• 736971-53-2 methyl 2-[(2,6-dichlorophenyl)methyl]-2-imidazoline-5-carboxylate 
• 459868-95-2 2,3-Bis-[(E)-3-(3,4-bis-methoxycarbonyloxy-phenyl)-acryloylamino]-propionic acid methyl ester 
• 897931-99-6 2,3-bis-(3,4-bis-methoxycarbonyloxy-benzoylamino)-propionic acid methyl ester 
• 897932-00-2 2,3-bis-(3,4,5-tris-methoxycarbonyloxy-benzoylamino)-propionic acid methyl ester 

Relevant academic research and scientific papers

Design and applications of new phosphine-free tetradentate Pd-catalyst: Regioselective C–H activation on 1-substituted 1,2,3-triazoles and indoles(NH-Free)

This article describes the synthesis of a new phosphine free tetradentate Pd catalyst using dl-2,3-diaminopropionic acid. The complex was characterized by Mass, IR, and 1H NMR. The catalyst is air stable at room temperature and non-hygroscopic. Application of this new catalyst to regioselective C–H activation on 1-substituted 1,2,3-triazole and indoles with aryl iodides to get corresponding C-5 and C-2 arylated products with satisfactory yields. All the products were characterized by spectroscopic studies.

RADIOTRACER PRECURSOR BANI FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAME

The present invention relates to a radiotracer precursor for imaging of hypoxic tissues, a radiotracer and a method for preparing the same. The radiotracer precursor, BANI, includes a nitroimidazole functional group with a feature of retention in hypoxic

Contrast enhancement agents and method of use thereof

A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3/su

LABELLED COMPOUNDS THAT BIND TO ALPHA-V-BETA-3 INTEGRIN

The present invention concerns in vivo imaging and in particular a novel in vivo imaging agent of formula (I). Also provided by the present invention is a method for the preparation of the in vivo imaging agent of the invention, and precursor compounds useful in said method. The in vivo imaging agent of the invention is useful in the diagnosis of conditions where there is a deviation from normal in the expression of integrin αvβ3.

Fluorescent non-peptidic RGD mimetics with high selectivity for αvβ3 vs αiIbβ3 integrin receptor: Novel probes for in vivo optical imaging

Integrins are heterodimeric transmembrane protein receptors consisting of different α and β subunits. αvβ3 integrins are overexpressed on many tumor cells and tumor-associated angiogenic vessels, whereas αIIbβ3 is a receptor for, e.g., fibrinogen and mediates platelet aggregation. In this study, a near-infrared fluorescent imaging probe has been designed and synthesized by conjugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modeling design approach. Affinity values were determined, and in vitro cell binding assays and preliminary in vivo xenograft studies in nude mice were performed to evaluate target binding. Competition assays revealed excellent binding and selectivity to αvβ3 compared to that for αIIbβ3. In vitro, the probe showed high target binding on αvβ3-positive M-21 cells and negligible binding to αvβ3-negative MCF-7 cells. In vivo, the tracer is able to image target expression in U-87 xenografts with a maximum signal-to-noise ratio (SNR) of 2.5:1 at 24 h after injection.

NITROGENATED AROMATIC HETEROCYCLIC RING DERIVATIVE

The present invention provides a nitrogen-containing aromatic heterocyclic derivative represented by formula (I): [wherein W represents CR3 (wherein R3 represents a hydrogen atom or the like) or the like, R4 represents a hydrogen atom or the like, R5 represents a hydrogen atom or the like, R9 represents substituted imidazolyl, R12 and R13 may be the same or different, each represent a hydrogen atom or the like, R22 and R23 may be the same or different, each represent a hydrogen atom or the like, R24 represents a hydrogen atom or the like, Y represents C-R25 (wherein R25 represents a hydrogen atom or the like) or the like] or a pharmaceutically acceptable salt thereof and a FGFR inhibitor comprising, as an active ingredient, the nitrogen-containing aromatic heterocyclic derivative or the pharmaceutically acceptable salt thereof, or the like.

Highly enantioselective synthesis of (S)-α-alkyl-α,β- diaminopropionic acids via asymmetric phase-transfer catalytic alkylation of 2-phenyl-2-imidazoline-4-carboxylic acid tert-butyl esters

Image Presented An efficient enantioselective synthetic method for (S)-α-alkyl-α,β-diaminopropionic acid is reported. The asymmetric phase-transfer catalytic alkylation of N(1)-Boc-2-phenyl-2- imidazoline-4-carboxylic acid tert -butyl ester in the presenc

Acylated aminopropanediols and analogues and therapeutic uses thereof

The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.

Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof

The invention relates to the use of acyl glycerols and the nitrogen- and sulfur-containing analogues thereof in the therapeutic field, particularly in human health. The inventive compounds have advantageous pharmacological properties and are particularly of use for the prevention or treatment of neurodegenerative diseases.

Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f

The invention relates to the use of molecules, particularly in the fields of human and veterinary health and cosmetics. The inventive compounds are acylated aminopropanediols and the nitrogen- and sulfur-containing analogues thereof and have advantageous pharmacological and cosmetic properties. In particular, the inventive compounds can be used to prevent and/or treat dyslipidemias, cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, some cancers, dermatological diseases, and, in the field of cosmetics, to combat skin ageing and the effects of same, in particular the development of wrinkles and the like.